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Abstract
Introduction Compromised patterns of gene expression result
in genomic instability, altered patterns of gene expression and
tumour formation. Specifically, aberrant DNA hypermethylation
in gene promoter regions leads to gene silencing, whereas
global hypomethylation events can result in chromosomal
instability and oncogene activation. Potential links exist between
environmental agents and DNA methylation, but the
destabilizing effects of environmental exposures on the DNA
methylation machinery are not understood within the context of
breast cancer aetiology.
Methods We assessed genome-wide changes in methylation
patterns using a unique methylation profiling technique called
amplification of intermethylated sites (AIMS). This method
generates easily readable fingerprints that represent the
investigated cell line's methylation profile, based on the
differential cleavage of DNA with methylation-specific
isoschisomeric restriction endonucleases.
Results We validated this approach by demonstrating both
unique and reoccurring sites of genomic hypomethylation in four
breast carcinoma cell lines treated with the cytosine analogue 5-
azacytidine. Comparison of treated with control samples
revealed individual bands that exhibited methylation changes,
and these bands were excized and cloned, and the precise
genomic location individually identified. In most cases, these
regions of hypomethylation coincided with susceptible target
regions previously associated with chromosome breakage,
rearrangement and gene amplification. Similarly, we observed
that acute benzopyrene exposure is associated with altered
methylation patterns in these cell lines.
Conclusion These results reinforce the link between
environmental exposures, DNA methylation and breast cancer,
and support a role for AIMS as a rapid, affordable screening
method to identify environmentally induced DNA methylation
changes that occur in tumourigenesis.
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Introduction
DNA methylation is essential for growth and development,
as well as for the environmental responsiveness of mamma-
lian cells. Cellular processes such as X chromosome inac-
tivation [1], imprinting [2], tumour suppressor inactivation
[3], and the silencing of retroviral and transposable DNA
elements [4] have been shown to involve DNA methylation.
The broad functionality of DNA methylation in mammalian
cells validates the need for tight regulation of this process.
Approximately 70% of CpG dinucleotides in human DNA
are constitutively methylated, whereas most of the unmeth-
ylated CpGs are located in so-called CpG islands, within
which lie the promoters of transcribed genes [5]. These
unmethylated gene promoter regions are associated with
an open chromatin configuration and transcriptional activa-
tion [6].
Aberrant DNA methylation can disrupt cellular functions
that are essential for normal cell development in several
ways. Hypermethylation of tumour suppressor gene pro-
moter regions can lead to transcriptional inactivation and
the loss of protein expression [3,7-9]. Also, hypomethyla-
tion of the global genome can lead to genomic instability
that is exemplified by misalignments, DNA breakage, dele-
tions and duplications during DNA replication, as seen in
ICF (immunodeficiency, centromeric region instability, and
facial anomalies) syndrome and colorectal cancer [8,10].
Finally, DNA methylation is linked to tumourigenesis
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through mutational gene inactivation [9]. Deamination of
the methylated cytosine in CpG dinucleotides can lead to
cytosine to thymidine transitions and premature stop muta-
tions, which in turn lead to the inactivation of tumour sup-
pressor genes such as p53 and LDL receptor [11].
In recent years a large body of evidence has been gener-
ated that provides a link between aberrant DNA methylation
and breast cancer. Such promoter hypermethylation has
been shown to inhibit expression of genes such as tumour
suppressors BRCA1, E-cadherin, and p16INK4b [7,12,13],
and steroid receptors ERα,  PR, and RARβ2  [14-16].
Recent reports [17,18] showed that in some breast can-
cers AHRI (a normally maternally imprinted tumour sup-
pressor gene from the Ras  superfamily) can have its
paternal copy inactivated through promoter hypermethyla-
tion. In addition, global hypomethylation and satellite DNA
hypomethylation [19] has been observed in breast cancer.
High-performance liquid chromatography analysis of global
cytosine methylation revealed a 56% reduction in breast
tumours as well as a 47% reduction in breast carcinoma
cell lines as compared with normal tissue [20]. Interest-
ingly, analysis of ductal breast carcinomas showed loss of
heterozygosity due to chromosome 17 deletions in 70% of
tumours analyzed, and chromosome 16 deletions in 66% of
tumours analyzed [21]. In a similarly designed study [10],
deletions in ductal breast carcinomas were detected on
chromosomes 16q, 17p and 17q, as well as 8p and 13q.
Given this information, we felt that an improved under-
standing of the interplay between changes in methylation
and breast carcinogenesis would provide additional insight
into the potential cause and effect relationship between
these two processes. Much of our current understanding
comes from studies of methylation-modifying chemical
agents, notably the nucleoside analogue 5-azacytidine.
Early studies conducted in mouse embryonic cells [22]
identified 5-azacytidine as a differentiating agent that
induces muscle cell development, along with the global
loss of DNA methylation. During DNA replication, incorpo-
rated 5-azacytidine irreversibly binds DNA methyltrans-
ferase (DNMT)1, which prevents maintenance methylation
on site while depleting available cellular DNMT1, and cre-
ates cytotoxic DNA adducts [23,24]. Depletion of DNMT1
causes DNA replication to proceed, with progressive loss
of methylation. 5-Azacytidine-induced hypomethylation
affects global DNA as well as CpG islands in gene promot-
ers, where it is often associated with transcriptional upreg-
ulation [25]. There is a lengthening list of tumour-specific,
methylation-repressed genes that are reported to be reac-
tivated by 5-azacytidine or 5-aza–deoxycytidine, including
ERα  [26], hMLH1  [27] and P16  [28,29]. Treatment of
breast carcinoma cell lines with 5-azacytidine induces loss
of promoter methylation and transcriptional upregulation of
BRCA1 – a tumour suppressor gene that is critically impor-
tant in the aetiology of hereditary and sporadic breast can-
cers [30].
Chronic and/or acute exposure to environmental carcino-
gens can alter normal patterns of methylation tagging and
induce wide-ranging destabilizing changes in gene expres-
sion patterns that lead to cell transformation and tumouri-
genesis. One such environmental carcinogen is
benzo(a)pyrene (B[a]P), which is a polycyclic aromatic
hydrocarbon that is present in the cigarette smoke [31],
charcoal broiled food [32] and petroleum byproducts [33].
B(a)P and its cellular metabolite (B[a]P-7,8-hydrodiol-9,10-
epoxide) initiate a range of toxic effects. Analyses of the
mutational hot spots in the p53  gene revealed B(a)P
adduct formation [34]. B(a)P exposure of MCF-7 breast
carcinoma cells causes changes in expression of tumour
suppressor genes, particularly a decrease in BRCA1
expression and an increase in p53 [35,36]. Finally, some
earlier studies showed that cells exposed to B(a)P in tissue
culture exhibit a 12% loss of methylated cytosines [37],
and that B(a)P can inhibit methyltransferase activity in vitro
[38]. Recent advances in our understanding of epigenetics,
and the availability of new analytical tools have set the
stage for further analysis of the potential interplay between
environmental exposure and methylation in the context of
breast cancer.
A unique methylation profiling technique called amplifica-
tion of intermethylated sites (AIMS) has recently been
shown to generate easily readable fingerprints that repre-
sent the investigated cell line's methylation profile [39]. This
novel protocol is based on the differential cleavage of DNA
with methylation-specific isoschisomeric restriction endo-
nucleases. The resulting differentially displayed bands can
be excized and used for sequencing analysis. Our modifica-
tion of this protocol allows for the study of the effect of
chemical exposure on DNA methylation in tissue culture
models. The objective of the study was to analyze the effect
of 5-azacytidine on DNA methylation in breast carcinoma
cell lines, both globally using AIMS and specifically using
sequence analysis. Also, we verified the use of AIMS as a
tool for analysis of chemical exposure within the context of
the epigenetics of breast cancer following benzopyrene
treatment.
We demonstrated both unique and reoccurring sites of
genomic hypomethylation in four breast carcinoma cell
lines treated with 5-azacytidine. Comparison of treated ver-
sus control samples revealed individual bands that exhib-
ited methylation changes that coincide with susceptible
target regions previously associated with chromosome
breakage, rearrangement and gene amplification. Similarly,
hypomethylation responses following B(a)P treatment rein-
force a link between environmental exposures, hypomethyl-
ation and breast cancer.Available online http://breast-cancer-research.com/content/6/4/R329
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Methods
Cell culture
MCF-7 and HCC1806 (from American Type Culture Col-
lection) human breast carcinoma cell lines were grown in
150-mm plates in Dulbecco's modified Eagle's medium
(Invitrogen, Burlington, ON, Canada) supplemented with L-
glutamine (200 mmol/l), HEPES (10 mmol/l), penicillin
(100  µg/ml), streptomycin (100 µg/ml) and 10% foetal
bovine serum. MDA-MB-231 and MDA-MB-468 human
breast carcinoma cell lines were grown in Dulbecco's mod-
ified Eagle's medium-α. The cells were maintained in a
humidified incubator at 37°C with 5% carbon dioxide.
Chemical treatments
The cells are grown to 10–15% confluence before treat-
ment with 1 µmol/l 5-azacytidine in ddH2O or with 5 µmol/
l B(a)P in dimethyl sulphoxide. DNA was isolated at 48, 72
and 96 hours after treatment using DNAZOL Reagent
(Gibco BRL, Life Technologies, Burlington, ON, Canada),
as per the manufacturer's instructions.
Amplification of intermethylated sites
Cellular DNA methylation profile analysis was adapted from
the AIMS protocol [39]. Briefly, 1–2 µg genomic DNA was
digested with 20 U of the methylation-sensitive restriction
endonuclease SmaI (Amersham Biosciences, Baie d'Urfe,
PQ, Canada), leaving a blunt end. Subsequently, the DNA
was digested with 4 U of the methylation-insensitive
isoschisomer PspAI (Stratagene, La Jolla, CA, USA), leav-
ing a staggered end to which a specific adaptor was
ligated. Following both digestions and the adaptor ligation
reaction, the DNA was purified using the QIAquick® PCR
Purification Kit (Qiagen, Mississauga, ON, Canada). Adap-
tors MCF (5'-CCGGTCAGAGCTTTGCGAAT-3') and
BLUE (5'-ATTCGCAAAGCTCTGA-3'), adaptor-specific
PCR primers (5'-BLUE-CCGGG-TGG-3' + 5'-BLUE-
CCGGG-TCA-3') and PCR conditions were used as previ-
ously described [39]. The DNA samples were run on
SequaGel-6 acrylamide gels (National Diagnostics; pur-
chased from Diamed, Mississauga, ON, Canada), and
bands were visualized using MR film (Amersham Bio-
sciences) following 48–72 hours of exposure.
The bands that were used for sequence analysis were
located on the gel using the positional overlap from the
developed X-ray film, and then dissected from the gel and
rehydrated in 50 µl ddH2O. Following the PCR amplifica-
tion using the original primers and PCR conditions, the
products were ligated into pGEMT-Easy vector (Promega;
purchased from VWR Canlab, Mississauga, ON, Canada)
and cloned using Top 10 Competent cells (Amersham Bio-
sciences). Positive colonies were checked using EcoRI
restriction digests and grown in LB media overnight. The
insert-containing vectors was purified using GenElute Plas-
mid Miniprep Kit (Sigma-Aldrich, Oakville, ON, Canada)
and sequenced at the London Regional Genome Centre,
London, Ontario, Canada. The sequence homologies were
analysed using BLAST [40], which was followed by analy-
sis using Human Genome Browser software [41].
Sodium bisulfite sequencing
Total genomic DNA was isolated from human breast carci-
noma cell lines using DNAzol Reagent (Gibco BRL). We
used the sodium bisulfite protocol [42,43] to confirm the
methylation status of cytosines within the CpG island of a
band localized to chromosome 2 (2p24; PubMed acces-
sion RP11-414D15). This band has been shown to
become hypomethylated after 4 days of 1 µmol/l 5-azacyti-
dine treatment using the AIMS protocol. Briefly, 2 µl
(approximately 1 µg) genomic DNA was immobilized in 9 µl
2% low melting point agarose beads. Following sodium
hydroxide denaturation, the DNA was sodium bisulfite con-
verted and desulfonated. The beads were washed in 1× TE
and used directly for PCR.
The following nested sets of converted PCR primer oligo-
nucleotides used to amplify this chromosome 2 region
were synthesized by Sigma: outside forward primer, 5'-
TGGAGTAGAAAATATGGTT AGGAATATTGG-3'; out-
side reverse primer, 5'-CACTCACAACATCTAAAACTA-
CAAA CAACC-3'; inside forward primer, 5'-
TGGTGTTTTAGATGATGGTAGTGGG-3', and inside
reverse primer, 5'-ACAATAACATTCCTTCCTCCAC-3'.
The amplification conditions were five cycles at 94°C (45
s), 55°C (2 min) and 72°C (2 min), followed by 30 cycles
at 94°C (45 s), 55°C (1 min) and 72°C (1 min) using Taq
polymerase (Invitrogen). A final 10 min extension time at
72°C was also performed. The first PCR amplified con-
verted DNA beads using the outside set of nested primers.
The product was then diluted 10× and 1 µl was used as a
template DNA for the second PCR using the inside set of
primers. All PCR products were cloned using the p-GEM®-
T Easy Vector System I (Promega). Individual positive
clones were identified, and plasmid DNA was isolated by
GenElute™ Plasmid Miniprep Kit (Sigma) and manually
sequenced using the T7 Polymerase Sequencing Kit
(Amersham Biosciences). The inside forward primer was
used in the sequencing reactions and the products were
run on 6% denaturing polyacrylamide gels, dried and
exposed to Biomax MR film (Amersham Biosciences) for
24 hours.
Results
To analyze the effects of 5-azacytidine on global methyla-
tion patterns, four breast carcinoma cell lines – MCF-7,
MDA-MB 468, HCC1806, and MDA-MB 231 – were
grown in media supplemented with 1 µmol/l 5-azacytidine
for 48, 72 and 96 hours. The AIMS method was used to
generate easily readable fingerprints representing the cells'Breast Cancer Research    Vol 6 No 4    Sadikovic et al.
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methylation profiles, based on the differential cleavage of
DNA with methylation-specific isoschisomeric restriction
endonucleases. The loss of DNA methylation at the restric-
tion enzyme recognition sequence results in the blunt-
ended SmaI cut, disabling ligation of the adaptor to this
DNA fragment. This prevents the adaptor-specific PCR
amplification, ultimately leading to the loss of a band on the
AIMS gel.
We were able to clearly differentiate and isolate approxi-
mately 50 different bands on a single AIMS gel. The
number of bands showing hypomethylation compared with
the number of unaffected bands differed among the cell
lines (Fig. 1), but in all experiments the results were repro-
ducible for each particular cell line and treatment regimen
(data not shown). The arrows in Fig. 1 indicate a loss of
bands due to hypomethylation in the 5-azacytidine-treated
cell lines. In MCF-7 cells this effect was evident after 48
hours (Fig. 1a), whereas the other three cell lines exhibited
treatment-associated loss of bands after 96 hours. Interest-
ingly, MCF-7 cells under our experimental conditions exhib-
ited the shortest doubling time of the cell lines tested.
We were able to calculate the degree of hypomethylation
for each of the cell lines (Table 1), as indicated by the loss
of intense bands in treated versus nontreated cells shown
Figure 1
Fluorogram of amplification of intermethylated sites (AIMS) gel showing human breast cancer cell lines treated with 1 µmol/l 5-azacytidine for 48, 72  and 96 hours (+) Fluorogram of amplification of intermethylated sites (AIMS) gel showing human breast cancer cell lines treated with 1 µmol/l 5-azacytidine for 48, 72 
and 96 hours (+): (a) MCF-7, .(b) HCC1806, (c) MDA-MB231 and (d) MDA-MB468. Profiles of bands from different experiments are highly repro-
ducible with any particular cell line, whereas banding patterns of individual cell lines vary considerably. Banding patterns differ as the culture period 
is extended, reflecting increased hypomethylation of genomic DNA. Arrows indicate decreases in or loss of band intensity, which are indicative of 
hypomethylation. The numbered bands are those that were excized, further characterized and localized to specific sites in the genome (see Table 1). 
Arrowheads indicate loss of bands and hypomethylation that is apparently dependent on culture conditions.Available online http://breast-cancer-research.com/content/6/4/R329
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in Fig. 1. A progressive loss of methylation (43%) was
evident in MCF-7 cells as early as 48 hours after treatment
that increased up to 54% at 96 hours. Hypomethylation
events were also seen in the other three cell lines but only
at the 96-hour time point, and the number of events was
less than with the MCF-7 cells. In Fig. 1b,1c,1d (arrow-
heads), we also observed a number of hypomethylation
events not associated with exposure to 5-azacytidine, as
signified by the loss of bands in both treated and untreated
cells. Interestingly, this effect was seen after 96 hours,
when confluence of the cells in the culture was close to
100%.
The arrows in Fig. 1 (1–12) indicate the bands showing 5-
azacytidine-induced hypomethylation that were later
excized and used for sequence analysis. The bands tar-
geted for sequencing were excized from the dried gels,
rehydrated, PCR amplified and cloned. The clones ranged
between 107 and 481 nucleotides in length and were char-
acterized for their genomic location, BLAST homology and
localization within genes or repetitive DNA elements (Table
2). The identities of most individual bands were either
unique to a particular cell line, or in some cases the bands
represented sequences that were common to more than
one cell line. For example, bands 1 and 4 were unique to
the MCF-7 line whereas band 3 in MCF-7 cells was identi-
cal to those sequenced, isolated and characterized from
MDA-MB 231 and MDA-MB 468 cells (bands 8 and 11).
The 12 bands were mapped to locations throughout the
genome, including chromosomes 2, 7, 9, 10, 11 and 21.
Using the BLAST homology results [40] and human
genome browser software [41], some bands were localized
within known gene sequences (band 2, 3, 6, 8, 9, 11, or
12) or within repetitive DNA elements (band 5). Bands 1,
4, 7 and 10 did not map to any known genes.
To verify that the loss of a band visualized using the AIMS
protocol was due to loss of methylation at SmaI/PspAI
sites, we performed sodium bisulfite sequencing of 5-aza-
cytidine treated versus untreated cells using primers spe-
cific to the DNA sequence represented in band 2 (Table 1).
All of the PCR clones were isolated and sequenced, and all
clones from the untreated cells exhibited DNA methylation.
In contrast, the treated cells produced a mixed population
of clones, with six out of 10 clones analyzed exhibiting a
clear loss of methylation at the restriction enzyme cut site
(Fig. 2).
After establishing that AIMS provides sensitive and repro-
ducible results with the known demethylating agent 5-aza-
cytidine, we analyzed the effect of the known environmental
carcinogen B(a)P. The MCF-7 and MDA-MB 231 cell lines
were treated with 5 µmol/l B(a)P for 48, 72 and 96 hours
(Fig. 3). The changes in banding patterns were most evi-
dent after 96 hours. Arrows indicate the loss of methylation
caused by B(a)P treatment. At the 96-hour time point, sev-
eral hypomethylation events were also evident in both
treated and untreated cells (arrowheads), perhaps due to
cell culture conditions as the cells neared 100%
confluence.
Discussion
AIMS is a novel protocol that was initially developed as a
screening tool for global methylation patterns, in the analy-
Table 1
5-Azacytidine induced hypomethylation analysis in the breast carcinoma cells
Cell line Time point Number of intense bands % Hypomethylation
MCF-7 48 hours 41 43.90
72 hours 41 43.90
96 hours 41 53.65
HCC1806 48 hours 23 0
72 hours 23 0
96 hours 22 36.36
MDA-MB 231 48 hours 29 0
72 hours 29 0
96 hours 26 11.53
MDA-MB 468 48 hours 24 0
72 hours 24 0
96 hours 17 23.52
The number of intense bands as observed is indicated for the nontreated lanes of each cell line from Fig. 1 at each time point. The percentage 
hypomethylation for each cell line at each time point is shown as percentage loss of bands compared with the corresponding nontreated lane.Breast Cancer Research    Vol 6 No 4    Sadikovic et al.
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sis of tumour samples [39]. Our laboratory has adopted
this protocol for the methylation analysis of chemical
exposure in breast cancer cell lines. We used the estab-
lished DNA hypomethylation agent 5-azacytidine [22-24] to
prove the effectiveness and reproducibility of the protocol
in tissue culture. In our hands the AIMS protocol permitted
identification of bands ranging in size from 107 to 481
nucleotides, which could later be isolated, cloned and
sequenced. This broad range of sizes allows for analysis of
many bands from a single AIMS gel. Bands showing differ-
ential display between the untreated and treated cells rep-
resent specific sequences throughout the genome that
become hypomethylated at the restriction sites. This tech-
nique is an effective way to access the global effect on
methylation of chemical treatment in cell culture. In cases in
which the sequence of a band overlaps with a gene or other
potentially interesting region, a more specific technique
such as sodium bisulfite sequencing can be used for fur-
ther analysis.
Four breast carcinoma cell lines – MCF-7, 1806, MDA-MB
231 and MDA-MB 468 – were used in our analyses. The
identical band profiles between different time points of the
untreated cells in a specific cell line indicate the high repro-
ducibility of the protocol (Fig. 1). For example, MCF-7 cells
have identical band patterns between the untreated sam-
ples at all three time points. This is also the case in other
three cell lines with the exception of some individual bands
at the 96-hour time point, as indicated by arrowheads. A
possible reason for this treatment-independent hypometh-
ylation might involve changes in the cell culture conditions
as the cells approach 100% confluence at the 96-hour time
point. Changes in environmental conditions often result in
altered patterns of gene expression, which has in many
cases been associated with methylation-associated chro-
matin rearrangements [44].
To establish the validity of AIMS protocol we used sodium
bisulfite sequencing to verify that the loss of the band on
Table 2
Sequence analysis of isolated, hypomethylated bands
Cell line/
band
Band
size
Location BLAST homology (region) Gene(s) Details Tissue/tumour type
MCF-7
1 395 7p14.3 RP11-162O1 (61998-61604) None NA NA
2 297 2p24.1 RP11-414D15 (178657-178361) BC013982, AL834515 mRNA (UP) Choriocarcinoma, 
melanoma
3 183 9q34.3 RP11-413M3 (36274-36092) AF032387 snRNA activating 
protein
Foetal cell 
teratocarcinoma
4 107 21q22.1 AP001713 (9409-9303) None NA NA
HCC1806
5 481 9q31.2 RP11-438P9 (61700-61218) MIRb SINE repeat NA
6 297 2p24.1 RP11-414D15 (178657-178361) BC013982, AL834515 mRNA (UP) Choriocarcinoma, 
melanoma
7 197 11q13.3 RP11-211G23 (138454-138261) None NA NA
MDA-MB 231
8 183 9q34.3 RP11-413M3 (36274-36092) AF032387 snRNA activating 
protein
Foetal cell 
teratocarcinoma
9 156 11q13 CTD-3074O7 (121538-121383) M86407, AK125851 α-actinin 3 Foetal skeletal muscle
10 122 10q26 RP13-137A17 (59898-60011) None NA NA
MDA-MB 468
11 183 9q34.3 RP11-413M3 (36274-36092) AF032387 snRNA activating 
protein
Foetal cell 
teratocarcinoma
12 156 11q13 CTD-3074O7 (121538-121383) M86407, AK125851 α-actinin 3 Foetal skeletal muscle
Band size, location, and BLAST homology were determined using BLAST [40]. Genes, details and expressing tissue were determined using 
human genome browser software [41]. 'Tissue/tumour type' refers to the particular cell type or carcinoma in which these mRNAs were previously 
shown to be expressed. UP, unknown protein.Available online http://breast-cancer-research.com/content/6/4/R329
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the AIMS gel represents the loss of methylation at the
SmaI/PspAI cut site. The sequence corresponding to band
2 at 2p24.1 was analyzed in MCF-7 cells at the 96-hour
time point. All of the clones isolated from the untreated
cells exhibited methylation at the central cytosine of the
restriction site, characterized by its insensitivity to the con-
version with sodium bisulfite (Fig. 2b). In contrast, in the 5-
azacytidine-treated cells there was a mixed population of
converted and unconverted clones, indicating a loss of
methylation at this site (Fig. 2c). This result is indicative of
variable methylation of one of the two SmaI/PspAI restric-
tion enzyme sites within this template. The gradual process
of demethylation occurring during prolonged exposure to
5-azacytidine in culture leads to an increased number of
sites for SmaI digestion over time. This creates blunt ends
that prevent ligation of the adaptors containing the primer
sequences that initiate PCR amplification. In addition, pre-
viously methylated sites that become hemimethylated by
replication for only one round without maintenance methyl-
ation will not be detected as unmethylated in their assay.
These bisulfite results thus provide additional insight into
the AIMS protocol. As well as being able to detect com-
plete demethylation [39], our results indicate that AIMS is
sensitive to decreases in methylation at a particular restric-
tion enzyme cut site, and suggest that global changes in
methylation as a response to a chemical treatment in cell
culture can be viewed as a gradual process occurring over
successive cell cycles.
We found that some of the hypomethylation events we
observed appeared to be targeted to common susceptible
sequences in the four cell lines we tested. Bands 3, 8 and
11 are identical, representing sequence located within the
SNAP190 gene on 9q34.3 that were recovered from MCF-
7, MDA-MB 231 and MDA-MB 468 cell line (Table 2). Also,
bands 2 and 6, as well as bands 9 and 12, were identical
and were recovered from MCF-7 and 1806, and MDA-MB
231 and MDA-MB 468 cells, respectively. Bands 2 and 6
represent a sequence located within the BC013982 gene,
whereas bands 9 and 12 encode sequences within the α -
actinin 3 gene (AK125851). Furthermore, SNAP190  is
found to be expressed in foetal teratocarcinoma cells,
whereas  BC013982  and  AL834515  are mRNAs with
Figure 2
Sodium bisulfite verification of amplification of intermethylated sites  (AIMS) protocol Sodium bisulfite verification of amplification of intermethylated sites 
(AIMS) protocol. (a) AIMS gel of untreated (-) MCF-7 cells and cells 
cultured in the presence (+) of 1 µmol/l 5-azacytidinecytidine for 96 
hours. Arrow indicates the band that was excised, cloned and 
sequenced following sodium bisulfite analysis. The methylation status 
of the SmaI/PspAI restriction enzyme site was confirmed by sequenc-
ing the sodium bisulfite converted DNA from the (b) control and (c) 1 
µmol/l 5-azacytidine-treated MCF-7 DNA cells.
Figure 3
Fluorogram of amplification of intermethylated sites (AIMS) gel showing  human (a) MCF-7 and (b) MDA-MB231 breast cancer cells treated  with 5 µmol/l benzopyrene for 48, 72 and 96 hours (+) Fluorogram of amplification of intermethylated sites (AIMS) gel showing 
human (a) MCF-7 and (b) MDA-MB 231 breast cancer cells treated 
with 5 µmol/l benzopyrene for 48, 72 and 96 hours (+). Banding pat-
terns differ increasingly as the culture period is extended, reflecting 
increasing hypomethylation of genomic DNA. Arrows indicate 
decreases in or loss of band intensity, which that are indicative of 
hypomethylation. Arrowheads indicate loss of bands and hypomethyla-
tion that is apparently dependent on culture conditions.Breast Cancer Research    Vol 6 No 4    Sadikovic et al.
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unknown function that are expressed in choriocarcinoma
and melanoma cells, respectively [41].
A previous study of squamous cell carcinomas that ana-
lyzed genomic instability using comparative genomic
hybridization identified chromosomal regions with signifi-
cant chromatin rearrangements involving deletions and
multiplications [45]. It is interesting to note in the present
study that eight out of the 12 bands exhibiting 5-azacyti-
dine-associated hypomethylation in Table 1 belong to
regions associated with genomic instability in the squa-
mous cell carcinomas. Specifically, bands 4 and 10 belong
to regions that have been shown to be often deleted in
squamous cell carcinomas, whereas bands 3, 7, 8, 9, 11
and 12 are located in regions of frequent multiplication.
These data suggest that there are regions of the genome
that are susceptible to hypomethylation, thereby creating
the sites of genomic instability [19,46]. Another interesting
point to consider relates to the regions that maintain their
methylation patterns following 5-azacytidine treatment.
Although some of these sequences may escape demethyl-
ation by chance, it is possible that the cell may actively act
to protect specific sequences from inappropriate demeth-
ylation because such a change may result in deleterious
consequences for the cell, including inappropriate gene
expression or an increased risk for hypomethylation-medi-
ated genomic instability [46]. In any event, the establish-
ment and maintenance of DNA methylation patterns is
dynamic and of critical importance in eukaryotic cells.
Finally, to establish the applicability of this technique to the
analysis of chemical exposure in tissue culture, we analyzed
the effect of the environmental carcinogen benzopyrene on
MCF-7 and MDA-MB 231 cells. Our results show the pre-
dominant loss of methylation in cells exposed to 5 µmol/l
B(a)P at the 96-hour time point, as indicated by arrows in
Fig. 3. These findings are consistent with early studies
showing a 12% decrease in methylation of cells exposed to
micromolar B(a)P [37], as well as showing methyltrans-
ferase inhibition due to B(a)P exposure in vitro [38]. As with
the previous experiments with 5-azacytidine, AIMS is sensi-
tive enough to identify specific changes in DNA methylation
that appear to be due to changes in culture conditions or
confluency over the duration of the experiments.
Conclusion
We provide evidence of global hypomethylation effects in
multiple breast carcinoma cell lines exposed to 5-azacyti-
dine or benzopyrene. Such hypomethylation may be tar-
geted to a common set of susceptible regions in the
genome. The toxic effects of B(a)P in the form of DNA
adduct formation, as well as in the modulation of gene
expression, are an area of interest in the context of cancer
and environmental exposure [34-36]. Our data provide new
insight into involvement of aberrant DNA methylation as a
target for environmental exposures contributing to breast
tumourigenesis and support a role for AIMS as a rapid,
affordable screening method with which to identify environ-
mentally induced DNA methylation changes in
tumourigenesis.
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